Information Provided By:
Fly News Breaks for June 13, 2018
IMGN
Jun 13, 2018 | 07:13 EDT
H.C. Wainwright analyst Debjit Chattopadhyay says the recent financing-related pullback in shares of ImmunoGen provides a compelling entry point. The capital raise takes ImmunoGen into its potential marketing approval in 2020, Chattopadhyay tells investors in a research note. He reiterates the stock as one of his firm's top SMID-cap ideas heading into the readout of the Forward I study during the first half of 2019. The analyst keeps a Buy rating on ImmunoGen with an $18 price target.
News For IMGN From the Last 2 Days
There are no results for your query IMGN